Skip to main content Back to Top
Advertisement

5/5/2023

Dobutamine Injection

Products Affected - Description

    • Dobutamine injection, Pfizer, 1 mg/mL, 250 mL premixed bag, 12 count, NDC 00409-2346-32
    • Dobutamine injection, Pfizer, 12.5 mg/mL, 20 mL vial, 1 count, NDC 00409-2344-01
    • Dobutamine injection, Pfizer, 2 mg/mL, 250 mL premixed bag, 12 count, NDC 00409-2347-32
    • Dobutamine injection, Pfizer, 4 mg/mL, 250 mL premixed bag, 12 count, NDC 00409-3724-32

Reason for the Shortage

    • Baxter had dobutamine on shortage due to manufacturing delays of a third-party supplier.
    • Pfizer has dobutamine on shortage due to manufacturing delays. FDA has approved extended expiry for several dobutamine presentations. These will be available at https://www.fda.gov/drugs/drug-shortages/search-list-extended-use-dates-assist-drug-shortages.

Available Products

    • Dobutamine injection, Baxter, 1 mg/mL, 250 mL premixed bag, 12 count, NDC 00338-1073-02
    • Dobutamine injection, Baxter, 2 mg/mL, 250 mL premixed bag, 12 count, NDC 00338-1075-02
    • Dobutamine injection, Baxter, 4 mg/mL, 250 mL premixed bag, 12 count, NDC 00338-1077-02
    • Dobutamine injection, Pfizer, 12.5 mg/mL, 20 mL vial, 10 count, NDC 00409-2344-02

Estimated Resupply Dates

    • Pfizer has dobutamine 1 mg/mL 250 mL premixed bags on back order and the company estimates a release date of May 2023. The 2 mg/mL 250 mL premixed bags are on back order and the company estimates a release date of June 2023. The 4 mg/mL 250 mL premixed bags are available in limited supply. The 12.5 mg/mL 20 mL vials in 1 count are on back order and the company estimates a release date of June 2023.

Alternative Agents & Management

    • Additional information can be found in a guidance document at: https://www.acc.org/Latest-in-Cardiology/Articles/2022/08/02/12/42/What-You-Need-to-Know-Guidance-For-Clinicians-on-Dobutamine-Shortage

Updated

Updated May 5, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 1, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.